Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVALT-17: Erlotinib versus cisplatin + pemetrexed + erlotinib in EGFR-mutated advanced NSCLC
NL-OMON27429Phase 3Not yet recruiting
- Sponsor
- NVALT
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of erlotinib, cisplatin and pemetrexed in non-small cell lung cancer (NSCLC) (2 arms), sponsored by NVALT. Primary endpoint: Progression-free survival. Planned start Mar 2014; status: not yet recruiting.
02
Drugs
erlotinibcisplatinpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON27429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27429.